Cutaneous metastasis as the first sign of small-cell cancer: An unexpected presentation in a patient with concurrent prostate cancer

Yana Kost, BA, Daiva M. Mattis, MD, PhD, Ahava Muskat, BS, Roya Nazarian, MD, Bijal Amin, MD, Haiying Cheng, MD, PhD, and Beth N. McLellan, MD

Key words: cutaneous metastasis; prostate cancer; radiation port; radiotherapy; lung cancer.

INTRODUCTION

Cutaneous metastasis as the first sign of malignancy in a patient with no other clinical symptoms is extremely rare.1 We report the case of a patient presenting with a solitary groin metastasis as the initial manifestation of small-cell carcinoma (SCC) of likely pulmonary origin.2 Of note, the patient was concurrently receiving radiotherapy (RT) treatment near the groin for stage IIC (cT1cN0M0) high-risk prostate adenocarcinoma. Studies suggest that RT may stimulate previously circulating tumor cells to hone to the skin, which may explain the unusual site of the cutaneous metastasis. Our report demonstrates the diagnostic power of skin biopsy, which led to a new diagnosis of metastatic SCC in this case.

CASE REPORT

A 58-year-old African American man with a 15-pack year smoking history and stage IIC high-risk prostate adenocarcinoma treated with 6 months of androgen deprivation therapy and ongoing intensity-modulated RT presented to our dermatology clinic with a 2-week history of a rapidly enlarging, painful left groin nodule. Examination revealed a tender, erythematous 3-cm nodule with central erosion and purulent odorous drainage (Fig 1, A). The nodule developed 4 weeks after RT initiation for prostate cancer at a standard dose of 41.4 Gy in 23 fractions, with treatment planned for 77.4 Gy in 43 fractions. The patient tolerated RT well and denied constitutional symptoms. A shave biopsy was conducted as part of the differential diagnosis, which included keratoacanthoma and cutaneous metastasis.

Biopsy demonstrated clusters and sheets of basa-

From the Division of Dermatology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.

Funding source: None.

IRB approval status: Not applicable.

Correspondence to: Beth N. McLellan, MD, Department of Medicine, Division of Dermatology, Montefiore Medical Center, Albert Einstein College of Medicine, 3411 Wayne Avenue, Bronx, NY 10467. E-mail: bmclela@montefiore.org.

JAAD Case Reports 2022;26:104-6.
2352-5126
© 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2022.05.034
soft tissue density in the left lung hilum (8.2 × 5.2 cm), mediastinal nodes, a mass in the body of the pancreas (5.8 × 5.2 cm), several foci in the liver, intramuscular right posterior neck, and subcutaneous left medial proximal thigh. Laboratory results revealed normal PSA (0.2 ng/mL), elevated lactate dehydrogenase (308 U/L; reference normal, <240 U/L) as well as leukopenia (0.5 k/µL; reference normal, 1.0-4.8 k/µL), and monocytosis (0.7 k/µL; reference normal, 0.3-0.5 k/µL).

Based on pathology findings, the dominant lung lesions, and widespread disease, the oncology team felt that extensive-stage pulmonary SCC was most probable, although its origin was not confirmed via lung lesion biopsy. The patient completed RT for prostate adenocarcinoma and started treatment with carboplatin, etoposide, and atezolizumab for the newly diagnosed pulmonary SCC. The dermatology team prescribed topical 0.75% metronidazole cream for bacterial colonization. After 1 chemotherapy cycle, the examination revealed a flatter nodule with several new satellite pink papules (Fig 1, B) and decreased purulence and odor resolution. After 2 cycles of chemotherapy, the patient had decreased pain, minimal drainage, and regression of surrounding papules (Fig 1, C). Imaging revealed a marked decrease in the left hilar mass size to 1.2 × 2.5 × 2.2 cm, with regions previously suspicious for malignancy found to be within normal limits.

**DISCUSSION**

Cutaneous metastasis as the first presentation of a visceral malignancy is extremely rare. While the pulmonary origin of malignancy was not confirmed, imaging and histologic evidence suggested a pulmonary primary. Of note, the patient’s lesion may also represent a cutaneous metastasis of neuroendocrine prostate cancer (NEPC), a rare, aggressive prostate cancer escape variant resistant to androgen deprivation therapy. NEPC is histologically similar to other neuroendocrine tumors; it has high proliferative rates and often lacks prostate cancer marker expression, as seen in the present case. As the SCC variant of NEPC often metastasizes to the lung, it is important to consider the differential of lung SCC in patients with prostate cancer history. Like in our patient, NPEC presents in patients with high-risk prostate}

---

**Fig 1.** Cutaneous metastasis. A, The patient’s groin demonstrated a solitary, erythematous, well-circumscribed nodule with central erosion and purulent drainage. B, Follow-up revealed a flatter, indurated, eroded nodule with hemorrhagic crust but with several new surrounding pink papules. C, After 2 chemotherapy cycles, the lesion showed significant improvement in healing with minimal drainage and regression of surrounding papules.

**Fig 2.** Small-cell carcinoma. The hematoxylin-eosin stained image shows clusters of small rounds to oval basaloid cells with fine stippled chromatin, scant cytoplasm, and nuclear molding. Mitoses and apoptotic cells are abundant. The inset shows a TTF-1 immunohistochemical stained image that is strong and diffusely positive in this same cell population. (Hematoxylin-eosin stain; original magnification: ×200; Inset, TTF-1 stain; original magnification: ×200.)
cancer without subsequent PSA elevation.\textsuperscript{4,5} TTF-1, found to be positive in our patient, is positive in up to 90% of pulmonary SCC but in <50% of NEPC.\textsuperscript{5} NPEC commonly presents with locally invasive bladder or bowel disease and distinct bone lytic lesions, which our patient lacked.\textsuperscript{4} Furthermore, NPEC typically presents 39.7 months after a prostate cancer diagnosis, unlike our patient who presented earlier.\textsuperscript{6} Finally, response to chemotherapy favors a lung cancer primary.

Interestingly, the metastatic lesion was close to the radiation field for prostate cancer. Several cases of cutaneous metastasis of recurrent primary cancer in the RT field have been reported primarily in breast cancer,\textsuperscript{7} but to our knowledge, we report the first case of cutaneous metastasis as the first sign of new underlying malignancy near the RT field. While RT is intended to destroy malignant cells, basic science and clinical data indicate that under some circumstances, RT may stimulate metastasis, providing reasoning for why the cutaneous lesion may have occurred in the groin.\textsuperscript{8,9} Proposed mechanisms point to the development of an “immunocompromised district” more susceptible to tumors because of RT-induced vascular damage impeding lymphatic drainage and causing local hypoxia leading to local cytokine upregulation promoting metastasis.\textsuperscript{9} Both effects are not limited to irradiated tissues and may affect neighboring cells through gap junctions or soluble factors, a phenomenon known as the radiation-induced bystander effect.\textsuperscript{10} Conversely, others describe RT-induced inhibition of distant tumor growth through the abscopal effect.\textsuperscript{9} Such studies are limited and more research is needed to determine the effect of RT on metastases.

This case underscores the powerful diagnostic utility of a skin biopsy, which provided initial evidence for an internal malignancy in this case. RT may explain the unusual site of cutaneous metastasis in this presentation. In conclusion, metastatic skin disease should always be considered in patients with cutaneous nodules so that correct diagnosis and treatment to prolong survival may be initiated.

Conflicts of interest
None disclosed.

REFERENCES
1. Salemis NS, Veloudis G, Spiliopoulos K, Nakos G, Vrizidis N, Gourgiotis S. Scalp metastasis as the first sign of small-cell lung cancer: management and literature review. Int Surg. 2014;99(4):325-329. https://doi.org/10.9738/INTSURG-D-13-00070.1
2. Krathen RA, Orenge IF, Rosen T. Cutaneous metastases: a meta-analysis of data. South Med J. 2003;96(2):164-167. https://doi.org/10.1097/01.SMJ.0000053676.73249.E5
3. Kamal KC, Florea L, Kamal D, Alexandru DO, Kamal AM. Non-specific onset of pulmonary adenocarcinoma. Curr Health Sci J. 2018;44(4):381-386. https://doi.org/10.12865/CHSJ.44.04.10
4. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32(1):65-71. https://doi.org/10.1097/PAS.0b013e318058a96b
5. Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014;2(4):273-285.
6. Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7-18. https://doi.org/10.1016/j.ejca.2019.08.011
7. Hoyt BS, Cohen PR. Radiation port cutaneous metastases: reports of two patients whose recurrent visceral cancers presented as skin lesions at the site of previous radiation and literature review. Indian J Dermatol. 2014;59(2):176-181. https://doi.org/10.4103/0019-5154.127680
8. von Essen CF. Radiation enhancement of metastasis: a review. Clin Exp Metastasis. 1991;9(2):77-104. https://doi.org/10.1007/BF01756381
9. Vilalta M, Rafat M, Graves EE. Effects of radiation on metastasis and tumor cell migration. Cell Mol Life Sci. 2016;73(18):2999-3007. https://doi.org/10.1007/s00018-016-2210-5
10. Morgan WF. Non-targeted and delayed effects of exposure to ionizing radiation: I. Radiation-induced genomic instability and bystander effects in vitro. Radiat Res. 2003;159(5):567-580. https://doi.org/10.1667/0033-7587(2003)159[567:nadeoe]2.0.co;2